##
##
|||Page|
|---|---|---|
|Contents||Numbers|
|Legal and administrative|information||
|Report ofthe Trustees||3-10|
|Report ofthe Auditors||11-13|
|Statement offinancial|activities|14|
|Charity balance sheet||15|
|Notes forming part ofthe financial statements||16-25|
##
##
|Charity registration|Charity registration|number:
1129597|number:
1129597|number:
1129597|||
|---|---|---|---|---|---|---|
|Company|registration||number:
6876186||||
|Directors|and||||||
|Trustees:|||Dr Kevin Moreton|||24/11/15 —present|
||||DrJan Lowe|||17/05/18- present|
||||Dr Liz Miller|||13/08/18 —present|
||||Dr LeoJames|||28/03/19 —present|
||||Dr Anne Bertolotti|||05/11/20- present|
|Secretary:|||Mrs Josie Gowler|FCA||18/04/18 —present|
|Registered|||MRC Laboratory of Molecular||Biology||
|Office:|||Francis Crick Avenue||||
||||Cambridge
Biomedical Campus||||
||||Cambridge||||
||||CB2 OQH||||
|Auditors:|||Price Bailey LLP:||||
||||Tennyson
House||||
||||Cambridge
Business Park||||
||||Cambridge||||
||||CB4OWZ||||
|Bankers:|||Lloyds Bank PLC:||||
||||3Sidney Street||||
||||Cambridge||||
||||CB2 3BL)||||
|Solicitors:|||HCR Legal LLP:||||
||||50-60Station Road||||
||||Cambridge||||
||||CB12JH||||
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|||||||Total Year|Total Year|
|---|---|---|---|---|---|---|---|
||||||Expendable|01/10/22|01/10/21|
||||Unrestiicted|Restricted|Endowment|to|to|
||||Funds|Funds|Funds|30/09/23|30/09/22|
|||Note|E|E|E|E|E|
|In«ome:||||||||
|Donations and legacies||||||||
|Donations|||86,264|0|0|86,264|64,207|
|Grants Received|||0|70,159|0|70,159|0|
|Investment
Income||4|104,251|52,680|19,166|176,097|155,006|
|Trading income||14|179|0|0|179|172|
|Total Income||||122,839||||
|Expenditure
on:||||||||
|Charitable
Activities|||78,560|101,421||179,981|92,761|
|Trading Activities|||0|0||0|3|
|Total Expenditure||5|78,560|101,421||»9,9Sl||
|Net Gains/(Losses)||||||||
|on Investments|||72,653|36,863|13,412|122,928|(344,701)|
|Net (Expenditure)|/|||||||
|Income|||184,787|58,281|32,578|275,646|(218,080)|
|Transfers between|funds|||||||
|Net movement
in|funds||184,787|58,281|32,578|275,646|(218,080)|
|Fund Balances||||||||
|brought forward at||||||||
|01October 2022|||1,878,611|987,466|347,895|3,213,972|3,432,052|
|Fund Balances||||||||
|carried forward at||||||||
|30September 2023|||||||3,»,9|
##
##
##
||||||30/09/2023|30/09/2022|
|---|---|---|---|---|---|---|
|||||Notes|E|E|
|Fixed Assets|||||||
|Investments|||||2,975,034|2,852,106|
|TOTAL FIXEDASSETS|||||2,975,034|2,852,106|
|Current Assets|||||||
|Debtors: amounts|falling||due within one year|10|18,108|560|
|Cash at bank and in||hand|||515,277|382,021|
|TDTALCURRENTASSETS|||||533,385|382,581|
|Creditors: amounts||falling due within one year|||(18,801)|(20,715)|
|Net current assets|||||514,584|361,866|
|Net Assets|||||||
|Funds ofthe charity|||||||
|Unrestricted
Funds|||||||
|General
Funds|||||1,181,833|1,020,607|
|Designated
Funds|||||881,565|858,005|
||||||2,063,398|1,878,612|
|Restricted Funds|||||||
|Restricted
Funds|||||1,045,747|987,466|
|Expendable
Endowment|||Funds||380,473|347,894|
||||||1,426,220|1,335,360|
|Total Funds||||12|3,489,618||
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|||Total forthe|Total forthe|
|---|---|---|---|
|||Year|Year|
|||01/10/2022 to|01/10/2021 to|
|||30/09/2023|30/09/2022|
|||E||
|Individuals||65,651|10,641|
|Gift Aid||15,613|560|
|Corporate|Donors|0|53,006|
|Trusts||5,000|0|
||||64,207|
##
|||Total for the|Total forthe|
|---|---|---|---|
|||Year|Year|
|||01/10/2022 to|01/10/2021to|
|||30/09/2023|30/09/2022|
|||E|E|
|Interest Receivable||426|8|
|Dividends|received from Investments|175,671|154,998|
##
|||||Activites|Grant|Support||
|---|---|---|---|---|---|---|---|
|||||Undertaken|funding of|Costs|Total|
|||||Dire*ly|a*ivities|(Note 6)|Funds|
|||||E|E|E|E|
|Promotion|and advancement||of|||||
|education|and research|||47,924|123,640|8,417|179,981|
|Trading activities||||0|0|0|0|
|||||47,924|123,640|8,417|179,981|
|Analysis ofExpenditure||-Prior Year||||||
|||||Activites|Grant|Support||
|||||Undertaken|funding of|Costs|Total|
|||||Directly|activities|(Note 6)|Funds|
|||||6|E|E|E|
|Promotion|and advancement||of|||||
|education|and research|||44,499|40,317|7,945|92,761|
|Trading activities||||3|0|0|3|
|||||~84 819|40,317|||
|Analysis of|Support Costs|Support Costs|||||||
|---|---|---|---|---|---|---|---|---|
||||||||Total for the|Totalforthe|
||||||||Year|Year|
||||||||01/10/2022 to|01/10/2021 to|
||||||||30/09/2023|30/09/2022|
||||||||E|E|
|Professional|Fees||||||1,680|1,621|
|8ank Fees|||||||160|168|
|Trustee Indemnity
Insurance|||||||264|967|
|Accountancy|Services||||||13|13|
|Governance|Costs (See note|||7)|||6,300|5,176|
||||||||8,417||
|Analysis of|Governance
Costs||||||||
||||||||Totalforthe|Totalforthe|
||||||||Year|Year|
||||||||01/10/2022 to|01/10/2021to|
||||||||30/09/2023|30/09/2022|
||||||||E|E|
|Audit Fees|||||||6,300|5,176|
|Trustees'
remuneration|||||||||
|The trustees|received|no emoluments|||or reimbursed|expenses during the year (2022- ENil).|||
|During the year, insurance|||was purchased to indemnify||||the Trustees against default on their part. The cost||
|ofthe insurance
amounted||||to 6264 (2022 - 6967).|||||
|Fixed asset|investments||||||||
||||||||Totalforthe|Totalforthe|
||||||||Year|Year|
||||||||01/10/2022 to|01/10/2021 to|
||||||||30/09/2023|30/09/2022|
||||||||E|E|
|Market value as at 1st||October|||||2,852,106|2,896,807|
|Additions|||||||0|300,000|
|Disposal Proceeds|||||||0|0|
|Net investments
gains||/ (losses)|||||122,928|(344,701)|
|Market value as at 30th September|||||||2,975,034|2,852,106|
|Historical cost as at 30th September|||||||2,590,854|2,590,854|
|UK listed investments||are|represented||by:||||
|Investment|trusts and|unit|trusts||||2,975,034|2,852,106|
||||||||2,975,034|2,852,106|
##
||||||||Totalforthe|Total for the|
|---|---|---|---|---|---|---|---|---|
||||||||Year|Year|
||||||||01/10/2022to|01/10/2021 to|
||||||||30/09/2023|30/09/2022|
|||||||||E|
|Gift aid||accrued income|||||15,613|560|
|Prepayments|||||||2,495|0|
||||||||18,108||
|ll
Creditors: amounts|||falling due within|one year|||||
||||||||Total for the|Total for the|
||||||||Year|year|
||||||||01/10/2022to|01/10/2021 to|
||||||||30/09/2023|30/09/2022|
||||||||6|6|
|Accrue||Is|||||18,801|20,715|
|12a
Statement of Funds|||- current year||||||
||||||||Investment||
||||At|||Transfers|Gains/|At|
||||01/10/2022|Income|Expenditure|In/Out|(Losses)|30/09/2023|
||||6|6|E|E|6|F.|
|GeneralFund|||1,020,607|144,995|(25,429)||41,660|1,181,833|
|Oesignated|Funds||||||||
|Perutz Fund|||312,110|18,599|(1,500)||12,029|341,238|
|Milstein
Fund|||522,649|26,081|(49,245)||18,251|517,735|
|AstraZeneca|||||||||
|Lecture Series|||20,882|1,019|(2,386)||713|20,228|
|Michael|||||||||
|iseuberger|||||||||
|Studentship|||2,364|||||2,364|
|Total|||||||||
|Unrestricted||funds|1,878,611|190,694|(78,560)||72,653|2,063,398|
|Restrkted funds|||||||||
|Steitz (formerly Brenner)|||||||||
|Postdoc Pdze|||27,673|327|(21,733)||229|6,496|
|Sangamo Aaron King|||||||||
|Symposium|||3,588|0|(3,588)|||0|
|GSA/PAL Fund|||2,192|10|(2,014)|||195|
|Fidelity Bermuda|||0|70,159|(70,159)|||0|
|Jeantet|||||||||
|Ramakdshnan|||343,204|18,692|(3,927)||13,079|371,048|
|Jeantet Winter|||610,809|33,651|0||23,548|668,008|
||||987,466|122,839|(101,421)||36,863|1,045,747|
|Expendable|||||||||
|Endowments|||||||||
|Agouron|||240,758|13,264|||9,282|263,304|
|Grigg Fund|||107,137|5,902|||4,130|117,169|
||||347,895|19,166|||13,412|380,473|
|Total|||||||||
|restricted funds|||1,335,360|142,005|(101,421)||50,275|1,426,220|
|Totalfunds|||3,213,972|332,699|(179,981)||122,928|3,489,618|
##
##
##
##
||||||||Investment||
|---|---|---|---|---|---|---|---|---|
||||At|||Transfers|Gains/|At|
||||01/10/2021|Income|Expenditure|ln/Out|(Losses)|30/09/2022|
||||E|E|E|E|E|E|
|General Fund|||1,096,930|57,084|(23,866)||(109,541)|1,020,607|
|Designated|Funds||||||||
|Perutz Fund|||331,290|15,819|(1,500)||(33,499)|312,110|
|Milstein
Fund|||597,302|25,224|(43,781)||(56,096)|522,649|
|AstraZeneca|||||||||
|Lecture Series|||3,876|21,008|(1,761)||(2,241)|20,882|
|Michael|||||||||
|Neuberger|||||||||
|Studentship|||2,067|297|0|||2,364|
|Total|||||||||
|Unrestricted|funds|||119,432|(70,908)||(201,377)|1,878,611|
|Restricted funds|||||||||
|Steitz (formerly||Brenner)|||||||
|Postdoc Prize|||11,138|34,341|(14,836)|0|(2,970)|27,673|
|Sangamo Aaron||idug|||||||
|Symposium|||10,497|173|(6,697)||(385)|3,588|
|GSA/PAL Fund|||0|2,606|(178)||(236)|2,192|
|Jeantet|||||||||
|Ramakrishnan|||363,621|16,564|(145)|0|(36,836)|343,204|
|Jeantet Winter|||646,888|29,479|0|0|(65,558)|610,809|
||||1,032,144|83,163|(21,856)|0|(105,985)|987,466|
|Expendable|||||||||
|Endowments|||||||||
|Agouron|||254,979|11,619||0|(25,840)|240,758|
|Grigg Fund|||113,464|5,171||0|(11,499)|107,137|
||||368,443|16,790||0|(37,339)|347,895|
|Total|||||||||
|restdcted funds|||1,400,588|99,953|(21,856)|0|(143,324)|1,335,360|
|Totalfunds|||3,432,052|219,385|(92,764)|0|i,70 i|3.2 3.9»|
##
##
##
##
##
##
##
##